Updates

Ergomed - "Hidden order bank"

October 2020

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

Another new high following H1 results to end June, exceeding more than half consensus expectations for the year so laying the way for upgrades to come. As it was, adjusted EBITDA increased 40% to £9.1m against expectations of £17m for the year. Sales were up 15% to £40.4m. Basic eps were 11.3p, up from 9.6p.The CRO business typically has contracts running for 18-30 months but was impacted by COVID-19 restrictions (site access and patient recruitment) and saw its underlying service fee revenue (excluding pass through costs) decline 7% to £11.1m. But despite that, gross margins went up. And COVID-19 has also provided opportunities and it is now involved in seven small scale COVID-19 trials and H2 looks stronger. The PV side no ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Playtech

PCI-PAL - Approaching paydirt

Ergomed - Permira bids 1350p (September 2023)

Ergomed - 80%+ of this year’s forecast covered (September 2022)

Ergomed - Well set for an eps ‘beat’ (August 2022)

Ergomed (April 2022)

Ergomed - Buys specialist consultancy for £25.6m (March 2022)

Ergomed (October 2021)

Ergomed (May 2021)

Ergomed (January 2021)

Ergomed - Another big "beat" (August 2020)

Ergomed - Forecasts lifted again - by 5% (July 2020)

Ergomed - COVID-19 trial work underway (April 2020)

Ergomed - Earnings accretive deal (February 2020)

Ergomed - Taking a share in a winning streak (October 2019)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X